As replacement or supplement therapy in patients with hypothyroidism of any aetiology (except transient hypothyroidism during the recovery phase of sub-acute thyroiditis): primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goitre; secondary (pituitary)
hypothyroidism; and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism.
For the suppression of pituitary Thyrotropin (TSH) in the treatment or prevention of various types of euthyroid goitres, including thyroid nodules, sub-acute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goitre and as an adjunct to surgery and radiolabelled iodine therapy in the management of TSH-dependent thyroid papillary carcinoma or well differentiated follicular carcinoma.
Adverse reactions different from those indicative of thyrotoxicosis as a result of therapeutic overdosage (either initially or during maintenance) are rare.In infants receiving hormone replacement therapy acraniosynostosis has been associated to latrogenic hyperthyroidism.
Inadequate dosage of the product may fail to resolve hypothyroidism symptoms.
There may be hypersensitivity reactions, such as rash and urticaria, to inactive ingredients in the product.
There may be partial hair loss during the early months of therapy, although this is generally transient.
Benign intracranial hypertension has been reported in children receiving levothyroxine therapy.